Omar Ben Hadj Salem1,2, Matthieu Jamme1, Marine Paul1,3, Lucie Guillemet1,3, Florence Dumas3,4,5, Frédéric Pène1,3, Jean-Daniel Chiche1,3, Julien Charpentier1,3, Jean-Paul Mira1,3, Hervé Outin6, Eric Azabou7,8, Alain Cariou1,3,4. 1. Medical Critical Care Unit, Cochin Hospital, Assistance Publique -Hôpitaux de Paris, Paris, France. 2. Intensive Care Unit, Centre Hospitalier Intercommunal Meulan- Les Mureaux, Meulan-en-Yvelines, France. 3. UFR de Médecine, Paris-Descartes-Sorbonne-Paris-Cité, Paris, France. 4. Paris Sudden-Death-Expertise-Centre, Paris, France. 5. Emergency Department, Cochin Hospital, Assistance Publique -Hôpitaux de Paris, Paris, France. 6. Intensive Care Unit, Poissy-Saint Germain en Laye, Centre Hospitalier Intercommunal, Poissy, France. 7. Clinical Neurophysiology and Neuromodulation Unit, Raymond Poincaré Hospital, Assistance Publique -Hôpitaux de Paris, Garches, France. eric.azabou@aphp.fr. 8. INSERM UMR1173 Infection and Inflammation (2I), University of Versailles-Saint Quentin (UVSQ), Paris Saclay University, 104 Boulevard Raymond Poincaré, 92380, Garches, Paris, France. eric.azabou@aphp.fr.
Abstract
BACKGROUND: Post-cardiac arrest myoclonus (PCAM) is a frequent finding in resuscitated patients after cardiac arrest (CA), with rather poor prognostic significance. In this study, we evaluated the association of PCAM within intensive care unit (ICU) mortality from a university hospital CA patients' registry. METHODS: Clinical data of consecutive CA survivors admitted in the intensive care unit (ICU) between January and December 2016 at the Paris Cochin University Hospital were assessed from the Parisian registry of cardiac arrest (PROCAT) and analyzed. Neurologic outcome was assessed using the Cerebral Performance Categories (CPC) scale at ICU discharge. Prevalence of PCAM and their association with mortality at ICU discharge were computed. RESULTS: One hundred thirty-two (132) patients were included (73.5% males), median age of 66 years. Among them, 37 (28%) developed PCAM during their ICU stay. Only two patients with PCAM survived (5.4%). PCAM was strongly associated with mortality at ICU discharge (odds ratio 17.5 [4.2-123.2]). Sensitivity, specificity, PPV, and NPV of PCAM for prediction of death were 41%, 96%, 95%, and 46%, respectively. CONCLUSION: PCAM was observed in nearly one-third of CA patients admitted in ICU. Patients with PCAM had a significantly higher likelihood of ICU mortality and a low likelihood of a good outcome. The prognostic value of PCAM seems rather bleak but remains nuanced and merits study in larger-scale prospective studies taking into account confounding factors.
BACKGROUND: Post-cardiac arrest myoclonus (PCAM) is a frequent finding in resuscitated patients after cardiac arrest (CA), with rather poor prognostic significance. In this study, we evaluated the association of PCAM within intensive care unit (ICU) mortality from a university hospital CA patients' registry. METHODS: Clinical data of consecutive CA survivors admitted in the intensive care unit (ICU) between January and December 2016 at the Paris Cochin University Hospital were assessed from the Parisian registry of cardiac arrest (PROCAT) and analyzed. Neurologic outcome was assessed using the Cerebral Performance Categories (CPC) scale at ICU discharge. Prevalence of PCAM and their association with mortality at ICU discharge were computed. RESULTS: One hundred thirty-two (132) patients were included (73.5% males), median age of 66 years. Among them, 37 (28%) developed PCAM during their ICU stay. Only two patients with PCAM survived (5.4%). PCAM was strongly associated with mortality at ICU discharge (odds ratio 17.5 [4.2-123.2]). Sensitivity, specificity, PPV, and NPV of PCAM for prediction of death were 41%, 96%, 95%, and 46%, respectively. CONCLUSION: PCAM was observed in nearly one-third of CA patients admitted in ICU. Patients with PCAM had a significantly higher likelihood of ICU mortality and a low likelihood of a good outcome. The prognostic value of PCAM seems rather bleak but remains nuanced and merits study in larger-scale prospective studies taking into account confounding factors.
Authors: Amy Z Crepeau; Alejandro A Rabinstein; Jennifer E Fugate; Jay Mandrekar; Eelco F Wijdicks; Roger D White; Jeffrey W Britton Journal: Neurology Date: 2013-01-02 Impact factor: 9.910
Authors: Jennifer E Fugate; Eelco F M Wijdicks; Jay Mandrekar; Daniel O Claassen; Edward M Manno; Roger D White; Malcolm R Bell; Alejandro A Rabinstein Journal: Ann Neurol Date: 2010-12 Impact factor: 10.422
Authors: Claudio Sandroni; Alain Cariou; Fabio Cavallaro; Tobias Cronberg; Hans Friberg; Cornelia Hoedemaekers; Janneke Horn; Jerry P Nolan; Andrea O Rossetti; Jasmeet Soar Journal: Intensive Care Med Date: 2014-11-15 Impact factor: 17.440
Authors: Jonathan C van Zijl; Martijn Beudel; Bauke M de Jong; Joukje van der Naalt; Rodi Zutt; Fiete Lange; Walter M van den Bergh; Jan-Willem J Elting; Marina A J Tijssen Journal: Ann Clin Transl Neurol Date: 2018-03-11 Impact factor: 4.511
Authors: Aline Bouwes; Daniël van Poppelen; Johannes H T M Koelman; Michael A Kuiper; Durk F Zandstra; Henry C Weinstein; Selma C Tromp; Eveline G J Zandbergen; Marina A J Tijssen; Janneke Horn Journal: BMC Neurol Date: 2012-08-01 Impact factor: 2.474